China Sows Ground For TCM Market Growth With Regulatory Framework
This article was originally published in The Tan Sheet
A long-awaited law could greatly enlarge the traditional Chinese medicine market and has prompted drug makers in the country to race to develop TCM products. The potential TCM boom has multinational drug firms leaping into the fray, some to partner with locals and others establishing teams devoted to TCM R&D.
You may also be interested in...
Bayer acquired its second Chinese consumer health care firm to gain market share amid the country’s OTC consolidation trend. Dihon specializes in antifungal creams and herbal drugs for women’s and traditional Chinese medicines.
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.